A-Methapred

Stevens-Johnson Syndrome, Pemphigus, Ophthalmia, Sympathetic + 45 more

Treatment

4 FDA approvals

20 Active Studies for A-Methapred

Treatment for

Stevens-Johnson Syndrome

What is A-Methapred

Methylprednisolone hemisuccinateThe Generic name of this drug

Treatment SummaryMethylprednisolone sodium succinate is an injectable form of the steroid methylprednisolone. It is used to treat cardiac emergencies, allergic reactions, and oxygen-related issues.

Solu-medrolis the brand name

image of different drug pills on a surface

A-Methapred Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Solu-medrol

Methylprednisolone hemisuccinate

1959

89

Approved as Treatment by the FDA

Methylprednisolone hemisuccinate, also known as Solu-medrol, is approved by the FDA for 4 uses including fulminating Pulmonary Tuberculosis and Tuberculous Meningitis .

fulminating Pulmonary Tuberculosis

Used to treat fulminating Pulmonary Tuberculosis in combination with null

Tuberculous Meningitis

Used to treat Tuberculous Meningitis in combination with null

disseminated Pulmonary Tuberculosis (TB)

Used to treat disseminated Pulmonary Tuberculosis (TB) in combination with null

Subarachnoid Block

Used to treat Subarachnoid Block in combination with null

Effectiveness

How A-Methapred Affects PatientsMethylprednisolone sodium succinate is a form of methylprednisolone that works in the same way to reduce inflammation. When given in the same amount, it has the same effects as methylprednisolone.

When to interrupt dosage

The suggested dosage of A-Methapred is contingent upon the recognized condition, including Idiopathic Thrombocytopenic Purpura, Multiple Sclerosis and Pure Red Cell Aplasia. The measure of dosage is contingent upon the administration approach (e.g. Injection, powder, lyophilized, for solution - Intramuscular; Intravenous or Kit; Powder, for solution) presented in the table beneath.

Condition

Dosage

Administration

Addison Disease

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Hypersensitivity

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Polymyositis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Temporal Arteritis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Brain

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Acute Coryza

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Palliative Treatment

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Dermatitis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Subarachnoid Block

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

disseminated Pulmonary Tuberculosis (TB)

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Stevens-Johnson Syndrome

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Ophthalmia, Sympathetic

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Berylliosis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Leukemias

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Multiple Sclerosis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Craniotomy

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Diuresis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Dermatomyositis (DM)

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Lupus Erythematosus

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Lupus

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection - Intramuscular; Intravenous, Injection, Kit; Powder, Kit; Powder, for solution, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous

Warnings

A-Methapred has three contraindications, and it should not be taken together with any of the disorders shown in the following table.A-Methapred Contraindications

Condition

Risk Level

Notes

intrathecal administration

Do Not Combine

Mycoses

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Methylprednisolone Hemisuccinate may interact with Pulse Frequency

There are 20 known major drug interactions with A-Methapred.

Common A-Methapred Drug Interactions

Drug Name

Risk Level

Description

Aldesleukin

Major

The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Methylprednisolone hemisuccinate.

Corticorelin ovine triflutate

Major

The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Methylprednisolone hemisuccinate.

Macimorelin

Major

The therapeutic efficacy of Macimorelin can be decreased when used in combination with Methylprednisolone hemisuccinate.

1,10-Phenanthroline

Minor

The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Methylprednisolone hemisuccinate.

Aceclofenac

Minor

The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Aceclofenac.

image of a doctor in a lab doing drug, clinical research

A-Methapred Novel Uses: Which Conditions Have a Clinical Trial Featuring A-Methapred?

207 active clinical trials are currently being conducted to assess the potential of A-Methapred in providing Palliative Care, Ulcerative Colitis and Eosinophilic Pneumonia relief.

Condition

Clinical Trials

Trial Phases

Secondary thrombocytopenia

0 Actively Recruiting

Berylliosis

0 Actively Recruiting

Addison Disease

0 Actively Recruiting

Craniotomy

1 Actively Recruiting

Phase 2

Eosinophilic Pneumonia

0 Actively Recruiting

exfoliative erythroderma

0 Actively Recruiting

Sarcoidosis

0 Actively Recruiting

Diuresis

0 Actively Recruiting

Malignant Neoplasms

0 Actively Recruiting

Stevens-Johnson Syndrome

1 Actively Recruiting

Phase 3

Polymyositis

3 Actively Recruiting

Phase 2, Phase 3

Lupus Erythematosus

4 Actively Recruiting

Phase 4, Not Applicable, Phase 1

Palliative Treatment

0 Actively Recruiting

Arthritis, Gouty

0 Actively Recruiting

Malignant Lymphomas

3 Actively Recruiting

Phase 1

induction of Diuresis

0 Actively Recruiting

Thyroiditis

0 Actively Recruiting

Leukemias

0 Actively Recruiting

Ulcerative Colitis

99 Actively Recruiting

Phase 2, Not Applicable, Phase 3, Phase 1, Phase 4, Early Phase 1

Rheumatoid Arthritis

61 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Patient Q&A Section about a-methapred

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does methylprednisolone?

"This medicine is only available with a prescription from a doctor. It works by helping to reduce inflammation, swelling, itchiness, and allergic reactions."

Answered by AI

What is Methapred used for?

"This medication can help treat a wide variety of conditions, including arthritis, blood disorders, severe allergies, cancer, eye conditions, and skin, kidney, intestinal, and lung diseases. It can also help to regulate the immune system."

Answered by AI

Clinical Trials for A-Methapred

Image of Mayo Clinic in Rochester, United States.

Patients with Pouchitis for Ulcerative Colitis

This trial investigates the use of intestinal ultrasound (IUS) in evaluating inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) patients with an ileal pouch-anal anastom

Waitlist Available

Mayo ClinicDarrell Pardi, MD

Image of University of Minnesota Medical School in Minneapolis, United States.

FT819 for Lupus

Minneapolis, MN

This trial will test a new drug, FT819, in participants with moderate to severe lupus. The study will first determine the safety and effects of different doses of the drug, followed by a larger

University of Minnesota Medical School (+1 Sites)Fate Therapeutics

Image of Swedish Medical Center in Seattle, United States.

SC291 for Microscopic Polyangiitis

This trial is testing a new drug called SC291 to see if it is safe and well-tolerated in people with severe autoimmune diseases. The study will also look at how the drug affects the body

Swedish Medical CenterPaul BrunettaSana Biotechnology

Image of VVCRD Research in Garden Grove, United States.

GS-1427 +1 More for Ulcerative Colitis

Garden Grove, CA

"This trial is testing a new drug, GS-1427, to see if it is safe and effective in treating people with moderate to severe ulcerative colitis. The study will compare different groups of

VVCRD Research (+5 Sites)Gilead Study DirectorGilead Sciences

Have you considered A-Methapred clinical trials? We made a collection of clinical trials featuring A-Methapred, we think they might fit your search criteria.

Explore trials for A-Methapred

Image of Atlantic Medical Research /ID# 258507 in Margate, United States.

Lutikizumab for Ulcerative Colitis

"This trial is testing a new drug called lutikizumab for treating ulcerative colitis (UC) by comparing it to an existing drug called adalimumab. Participants will be divided into

Atlantic Medical Research /ID# 258507 (+2 Sites)ABBVIE INC.AbbVie

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Gusacitinib for Lupus

"This trial is testing a new drug called Gusacitinib in people with lupus, a disease where the immune system attacks healthy tissue. The study will involve participants aged 18 and older and will

Waitlist Available

No Cost For Treatment

National Institutes of Health Clinical CenterSarfaraz A Hasni, M.D.

Image of Memorial Sloan Kettering Basking Ridge (Consent Only) in Basking Ridge, United States.

Participants with high-grade glioma for Brain Tumor

Basking Ridge, NJ

This trial aims to determine if a type of imaging test called 68Ga-PSMA-11 PET/CT can accurately measure tumor activity in participants with high-grade glioma or brain metastases.

Memorial Sloan Kettering Basking Ridge (Consent Only) (+6 Sites)Simone Krebs, MD

Image of University of Colorado in Aurora, United States.

SBT777101 for Rheumatoid Arthritis

This trial is testing a new treatment called SBT777101 for people with rheumatoid arthritis. The study will look at whether it is safe and how it affects the participants. The treatment will be

University of Colorado (+4 Sites)Mark Eisner, MDSonoma Biotherapeutics, Inc.

Have you considered A-Methapred clinical trials? We made a collection of clinical trials featuring A-Methapred, we think they might fit your search criteria.

Explore trials for A-Methapred

Image of Children's Hospital Colorado in Aurora, United States.

Temozolomide +1 More for Astrocytoma

This trial will test if a drug can extend the life of kids/young adults with a deadly brain tumor linked to a genetic mutation.

Waitlist Available

Children's Hospital Colorado (+11 Sites)Maryam Fouladi, MDRigel Pharmaceuticals

Image of Arthritis & Osteoporosis Medical Center - La Palma ( Site 0108) in La Palma, United States.

MK-6194 for Lupus

This trial is testing a medication called MK-6194 to see if it is effective and safe for adults with Systemic Lupus Erythematosus. The main goal is to find out if

Senior-friendly

Arthritis & Osteoporosis Medical Center - La Palma ( Site 0108) (+7 Sites)Medical DirectorMerck Sharp & Dohme LLC

Image of University of California, Los Angeles (UCLA) Medical Center in Los Angeles, United States.

IMPT-514 for Lupus

Los Angeles, CA

This trial will study the safety and effectiveness of a new infusion therapy for those with lupus nephritis or SLE, followed up for 15 years.

University of California, Los Angeles (UCLA) Medical Center (+4 Sites)ImmPACT Bio

Image of Tyler Research Institute, LLC in Tyler, United States.

Vixarelimab for Ulcerative Colitis

This trial aims to study the effectiveness, safety, and how the body processes vixarelimab compared to a placebo in people with moderate to severe ulcerative colitis who have not responded well to

Tyler Research Institute, LLC (+1 Sites)Clinical TrialGenentech, Inc.

Have you considered A-Methapred clinical trials? We made a collection of clinical trials featuring A-Methapred, we think they might fit your search criteria.

Explore trials for A-Methapred

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security